Lyell Immunopharma (LYEL) Stock Statistics & Valuation Metrics

Lyell Immunopharma has a market cap or net worth of $469.41M. The enterprise value is $409.59M.

Lyell Immunopharma has 23,307,142 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lyell Immunopharma’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -70.11%.

The current PE Ratio of Lyell Immunopharma is ―. Lyell Immunopharma’s PEG ratio is -0.00170.

In the last 12 months, Lyell Immunopharma had revenue of 36.00K and earned -274.45M in profits. Earnings per share was -16.06.

In the last 12 months, operating cash flow was -178.60M and capital expenditures -842.00K, giving a free cash flow of -179.44M billion.

Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lyell Immunopharma upcoming earnings date is May 12, 2026, After Close (Confirmed).

Lyell Immunopharma as a current ratio of 5.28, with Debt / Equity ratio of 16.89%

In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.

Lyell Immunopharma EV to EBITDA ratio is -2.64, with an EV/FCF ratio of -3.37.

Lyell Immunopharma has $247.22M in cash and marketable securities with $41.92M in debt, giving a net cash position of $205.30M billion.

Gross margin is -6558.33%, with operating margin of -566038.89%, and net profit margin of -762355.56%.

The average price target for Lyell Immunopharma is $39.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy